GlassScriptPhysician profile
Joseph F Panarelli
NPI 1194975177
$540,866.04
in general payments reported to CMS, 2019-2025
14 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $52K · 2021: $63K · 2022: $117K · 2023: $79K · 2024: $76K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Consulting Fee: $90K · Travel and Lodging: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $5,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,873.00 |
| Consulting Fee | $89,912.00 |
| Travel and Lodging | $16,957.94 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,500.00 |
| Food and Beverage | $5,159.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $147,604.74 | 2019-2022 | |
| Abbvie INC. | $143,882.14 | 2021-2025 | |
| Alcon Vision LLC | $116,636.30 | 2020-2025 | Rhopressa, Rocklatan, Simbrinza |
| Bausch & Lomb Americas INC. | $38,806.45 | 2022-2025 | Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $38,124.23 | 2019-2021 | |
| Glaukos Corporation | $22,739.15 | 2019-2025 | Travoprost Intraocular Implant - Idose, Istent Trabecular Micro-Bypass Stent System, Idose |
| Nova Eye, INC. | $17,658.91 | 2022-2023 | |
| Carl Zeiss Meditec, INC. | $8,823.79 | 2022-2024 | Clarus, Forum, Cirrus Hd-Oct |
| Thea Pharma INC. | $4,978.33 | 2023-2024 | Iyuzeh |
| New World Medical,INC. | $1,345.94 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $133.33 | 2020 | |
| Ocular Therapeutix, INC. | $99.43 | 2019-2020 | |
| Harrow Eye, LLC | $33.30 | 2025 | Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Panarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.